This article is more than 5 years old. Information may no longer be current.

Aerie reports $28.4 million net loss in second quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aerie Pharmaceuticals reported a net loss of $28.4 million, or $0.82 per share, in the second quarter of 2017 compared with a net loss of $23.2 million, or $0.87 per share, in the same quarter of 2016, according to a press release.

Research and development expenses totaled $10.6 million compared with $13.3 million in 2016, and selling, general and administrative expenses were $17.2 million compared with $9.4 million.

The increase in operating expenses was attributed to activities associated with expanding the company’s employee base to support its growth, including the commercial manufacturing of Rhopressa (netarsudil ophthalmic solution 0.02%), the release said.

Aerie had cash, cash equivalents and investments totaling $307.9 million as of June 30.